CIDRAP newsletters options
Use of second- and third-line antibiotics and fixed-dose combinations (FDCs) of antibiotics increased over a 10-year period at two Indian hospitals, a team of Swedish researchers reported yesterday in BMC Infectious Diseases.
Brazil reports 881 new COVID-19 deaths, its highest daily fatality count.
However, two thirds of US adults say it will not be safe for gatherings of 10 or more until midsummer.
Mathematical modeling explores several scenarios, including a resurgence as late as 2024.
A white paper published today in Infection Control and Hospital Epidemiology calls on antibiotic stewardship programs (ASPs) to take steps to address the potential legal implications of stewardship activities.
In a study yesterday in Morbidity and Mortality Weekly Report (MMWR), researchers describe a COVID-19 super-spreading event at a Washington state choir practice in March, which was attended by a symptomatic index patient and produced an attack rate of 53.3% to 86.7%.
Researchers says there's no question the novel virus originated in nature.
Fauci warns senators that states risk new and worsening COVID-19 outbreaks if they move too fast.
Vaccine development hinges on "unprecedented" and transparent efforts, top US experts say.
Russia reports almost 11,000 new cases, part of an ongoing surge mainly centered in Moscow.
A retrospective study of COVID-19 patients in New York City hospitals found that treatment with the antimalaria drug hydroxychloroquine, the antibiotic azithromycin, or both was not significantly associated with differences in in-hospital mortality compared with patients who received neither drug.
The WHO also warns that COVID-19 disruptions could hurt the battle against HIV.
73% of patients had respiratory symptoms, while 23% had failure of at least two organ systems.
Some 5,000 COVID-19 deaths in New York City might not have been counted, a new report says.
A low-intensity, multifaceted stewardship intervention implemented at nursing homes was associated with improved antibiotic prescribing for urinary tract infections (UTIs), US researchers reported today in JAMA Internal Medicine.
A phase 2 trial has shown that a 2-week course of triple antiviral therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin is safe and better at shortening COVID-19 viral shedding than lopinavir-ritonavir alone in patients with mild to moderate illness if started within 7 days of symptom onset.
Also, New York officials said 3 children have died from what might be a recently identified inflammatory complication.
In a poll, almost two thirds of Americans say they fear it's too soon to reopen the economy.
The drug was not tied to lower rates of intubation or death in COVID-19 patients.
The WHO voices concern over increased domestic violence in nations under stay-at-home orders.
